Day One Biopharmaceuticals (DAWN) Stock Forecast & Price Target

$16.64
+1.26 (+8.19%)
(As of 04/23/2024 ET)

Day One Biopharmaceuticals Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 8 Analyst Ratings

Analysts' Consensus Price Target

$39.83
139.38% Upside
High Forecast$50.00
Average Forecast$39.83
Low Forecast$34.00
TypeCurrent Forecast
4/24/23 to 4/23/24
1 Month Ago
3/25/23 to 3/24/24
3 Months Ago
1/24/23 to 1/24/24
1 Year Ago
4/24/22 to 4/24/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
7 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$39.83$40.60$42.60$43.57
Predicted Upside139.38% Upside185.35% Upside200.85% Upside128.46% Upside
Get Day One Biopharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for DAWN and its competitors with MarketBeat's FREE daily newsletter.

DAWN Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

DAWN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Day One Biopharmaceuticals Stock vs. The Competition

TypeDay One BiopharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.63
2.68
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside139.38% Upside988.26% Upside10.13% Upside
News Sentiment RatingPositive News
Neutral News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/22/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$32.00 ➝ $36.00+139.68%
3/26/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$40.00+166.31%
2/27/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$50.00 ➝ $44.00+163.63%
2/27/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMarket Perform ➝ Market Perform
11/7/2023Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$39.00 ➝ $35.00+176.90%
11/7/2023Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$34.00+178.92%
8/8/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$50.00+304.20%
4/25/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Underperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 10:00 PM ET.

DAWN Price Target - Frequently Asked Questions

What is Day One Biopharmaceuticals's consensus rating and price target?

According to the issued ratings of 8 analysts in the last year, the consensus rating for Day One Biopharmaceuticals stock is Moderate Buy based on the current 1 sell rating, 1 hold rating and 6 buy ratings for DAWN. The average twelve-month price prediction for Day One Biopharmaceuticals is $39.83 with a high price target of $50.00 and a low price target of $34.00. Learn more on DAWN's analyst rating history.

Do Wall Street analysts like Day One Biopharmaceuticals more than its competitors?

Analysts like Day One Biopharmaceuticals less than other Medical companies. The consensus rating score for Day One Biopharmaceuticals is 2.63 while the average consensus rating score for medical companies is 2.68. Learn more on how DAWN compares to other companies.

Does Day One Biopharmaceuticals's stock price have much upside?

According to analysts, Day One Biopharmaceuticals's stock has a predicted upside of 184.76% based on their 12-month stock forecasts.

What analysts cover Day One Biopharmaceuticals?

Day One Biopharmaceuticals has been rated by JPMorgan Chase & Co., Oppenheimer, Piper Sandler, and The Goldman Sachs Group in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:DAWN) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners